Corgenix Medical Corporation company was founded in 1985 and is headquartered in Broomfield, Colorado. Corgenix Medical Corporation, together with its subsidiaries, engages in the research, development, manufacture, and marketing of in vitro diagnostic products for use in disease detection and prevention in the United States and internationally. The company offers autoimmune disease products that are used for the diagnosis and monitoring of autoimmune diseases, including RA, SLE, mixed connective tissue diseases, Sjogren’s Syndrome, Dermatopolymyositis, and Scleroderma; and antiphospholipid antibody testing products, which are used in the diagnosis of clotting and bleeding disorders, including von Willebrand's disease. It also provides AspirinWorks, a urine test kit that measures an individual's response to aspirin dosage and allows physicians to adjust the dosage or recommend alternative therapy; and liver disease products, which include hyaluronic acid, a component of the matrix of connective tissues found in synovial fluid of the joints where it acts as a lubricant and for water retention. The company sells its products to hospitals, clinical testing laboratories, universities, biotechnology and pharmaceutical companies, and research institutions. It markets its products through a network of sales representatives, distributors, and private label agreements.

Poniard Pharmaceuticals was founded in 1984 and is headquartered in South San Francisco, California. Poniard Pharmaceuticals, Inc., together with its subsidiary, NeoRx Manufacturing Group, Inc., focuses on the development and commercialization of oncology products for people with cancer. Its lead platform product candidate, Picoplatin, is a platinum-based cancer therapy that is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Picoplatin is being studied in various cancer indications, combinations, and formulations. Poniard Pharmaceuticals is conducting a phase III clinical trial of intravenous picoplatin in small cell lung cancer; two phase II clinical trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers; and a clinical trial of oral picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in June 2006.

Trubion Pharmaceuticals, Inc.company was founded in 1999 and is headquartered in Seattle, Washington. Trubion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of protein therapeutic product candidates for the treatment of autoimmune and inflammatory diseases and cancer. The company, in a collaboration with Wyeth, is conducting a phase IIb clinical trial for its lead product candidate, TRU-015, for the treatment of rheumatoid arthritis. The company also offers TRU-016, a phase II/II clinical evaluation product and a novel CD37-targeted therapy for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia and certain autoimmune and inflammatory disease indications. It also has collaboration agreement with Wyeth for the development and commercialization of SBI-087 for the treatment of rheumatoid arthritis and SBI-087 for the treatment of systemic lupus erythematosus, as well as other therapeutics directed to CD20, an antigen that is a validated clinical target present on B cells.

Dow Pharmaceutical Sciences company researches and develops topical dermatological pharmaceutical and biotech products for external clients. It works to formulate the gel, ointment, or cream that will carry a client's drug, assesses its effectiveness, manufactures and packages product candidates for clinical trials, and provides regulatory affairs consulting. It provides contract research services through its Solano Clinical Research division in the US and its Bioskin subsidiary in Europe. Dow Pharmaceutical Sciences also develops dermatology products on a proprietary basis. The company is owned by Valeant Pharmaceuticals.

Bioheart, Inc. company was founded in 1999 and is headquartered in Sunrise, Florida. Bioheart, Inc. is a biotechnology company focused on the discovery, development and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic acute heart damage and peripheral vascular disease. MyoCell is a clinical therapy designed to populate regions of scar tissue within a patient’s heart with living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company’s clinical trials of MyoCell include the SEISMIC Trial, a completed 40 patient Phase II clinical trial conducted in Europe, and the MYOHEART Trial, a completed 20 patient, Phase I dose escalation trial conducted in the United States. In its pipeline, the Company has multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose cell treatment for acute heart damage, and MyoCell SDF-1, a therapy utilizing autologous cells genetically modified to express additional growth proteins.

Elusys Therapeutics is recruiting antibodies in its anti-terrorism campaign. Elusys Therapeutics company develops antibody therapies for a variety of targets, including anthrax. Its lead product Anthim has shown to be effective in combatting infections caused by anthrax up to 48 hours after exposure. When administered prior to exposure, the drug has proven to be 100% effective in preventing infections. Another drug candidate, Staph A Heteropolymer, targets staphylococcus infections, which have become increasingly prevalent and resistent to treatment. Other Elusys products target non-Hodgkin's lymphomas, lupus, and deep vein thrombosis.

Photopharmica Ltd. discovers and develops photo sensitizers and light sources for medical use in the United Kingdom. The company develops anti-infective agents primarily for dermatology and wound management markets; and medical devices in the fields of orthopedics and periodontal equipment. Its products pipeline includes phenothiazinium photo sensitizers for use as topical therapeutic antimicrobial agents; phenothiazinium photo sensitizers for systemic oncology use; and phthalocyanine photo sensitizers that combine anti-tumor properties with minimal or zero skin photo sensitization. Photopharmica Ltd. was founded in 2001 and is based in Leeds, the United Kingdom.

Nycomed US Inc. (formerly Altana Inc) is a subsidiary of Nycomed, which operates three divisions in the US focused on specialty pharmaceuticals in dermatology. Founded in 1849, Fougera is the largest of the three divisions and is a leading manufacturer and distributor of a wide range of multi-source topical steroids, antibiotics and antifungal products. The PharmaDerm division of Nycomed is dedicated to bringing innovative products to the dermatologists so they can best care for their patients. Nycomed US also markets and sells Savage Laboratories products, which focus on emergency care.

LGC (Holdings) Limited company provides chemical, DNA and other scientific analysis through four operating divisions: LGC forensics, life and food sciences, research and technology, and LGC standards. Its customers are involved in such areas as drug development, health care services, chemicals and petrochemicals, law enforcement, and environmental quality and maintenance. The company's LGC Prochem unit sells enzymes, proteins, reagents, and other laboratory supplies. Investment firm 3i Group owns about 30% of LGC, as does its employees.

Exelixis, Inc. company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California. Exelixis, Inc. discovers and develops small molecule drugs for the treatment of cancer, and various metabolic and cardiovascular disorders. Its products include XL184, a Phase 3 clinical trial compound that inhibits MET, RET, and VEGFR2, which drive tumor growth and vascularization, as well as Phase 1b/2 clinical trials compounds, including XL147 that targets phosphoinosotide-3 kinase (PI3K); and XL765, which targets PI3K and mTOR, kinases in the PI3K signaling pathway. The company has various compounds in phase 1 clinical trials, including XL518, a small molecule inhibitor of the MEK, a component of the RAS/RAF/MEK/ERK signaling pathway; XL228, which targets insulin-like growth factor type 1 receptor, an RTK in a range of human tumors; XL019 that inhibits JAK2, a cytoplasmic tyrosine; XL139, which inhibits activation of Hedgehog signaling; XL413, a small molecule inhibitor of the serine-threonine kinase CDC7; and XL888, a synthetic inhibitor of HSP90, a chaperone protein that promotes the activity and stability of a range of regulatory proteins, including kinases. In addition, its preclinical and clinical development stage products that are out-licensed to third parties for the development and commercialization include XL880, an inhibitor of MET and VEGFR2; XL281, which targets RAF, a cytoplasmic serine/threonine kinase; XL652 targeting liver X receptors, which modulate genes involved in regulation of lipid and cholesterol homeostasis; XL550, a non-steroidal mineralocorticoid receptor; and FXR Program that targets Farnesoid X Receptor, a bile acid receptor. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals; and Daiichi-Sankyo.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.